An Update of Safety and Efficacy Results oiii Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing Prior TKI Therapies

被引：3

作者：

Cortes, Jorge E. ^{[1
]}

Saikia, Tapan ^{[2
]}

Kim, Dong-Wook ^{[3
,4
]}

Alvarado, Yesid ^{[5
]}

Nicolini, Franck E. ^{[6
]}

Rathnam, Krishnakumar ^{[7
]}

Khattry, Navin ^{[8
]}

Apperley, Jane F. ^{[9
]}

Deininger, Michael W. ^{[10
]}

de Lavallade, Hugues ^{[11
]}

Charbonnier, Aude ^{[12
]}

Granacher, Nikki ^{[13
]}

Gambacorti-Passerini, Carlo ^{[14
]}

Lucchesi, Alessandro ^{[15
]}

Mauro, Michael J. ^{[16
]}

Vandenberghe, Peter ^{[17
]}

Verhoef, Gregor ^{[17
]}

Whiteley, Andrew R. ^{[18
]}

Nag, Arijit ^{[19
]}

Radhakrishnan, Vivek S. ^{[19
]}

Apte, Shashikant ^{[20
]}

Yao, Siu-Long ^{[21
]}

Inamdar, Sandeep ^{[22
]}

Sreenivasan, Jayasree ^{[22
]}

Dillu, Ruchika Irene ^{[22
]}

Chimote, Geetanjali ^{[22
]}

机构：

[1] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA

[2] Prince Aly Khan Hosp, Mumbai, Maharashtra, India

[3] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med,Dept Hematol, Seoul, South Korea

[4] Catholic Univ Korea, Seoul St Marys Hosp, Catholic Hematol Hosp, Coll Med, Seoul, South Korea

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Ctr Leon Berard, Hematol Dept, Lyon, France

[7] Meenakshi Mission Hosp & Res Ctr, Lake Area, Melur Main Rd, Madurai, Tamil Nadu, India

[8] Tata Mem Hosp, ACTREC, Dept Med Oncol, BMT Unit, Navi Mumbai, India

[9] Imperial Coll, Hammersmith Hosp, Ctr Haematol, Dept Med, London, England

[10] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[11] Kings Coll Hosp London, NHS Fdn Trust, Dept Haematol Med, London, England

[12] Inst Paoli Calmettes, Dept Hematol, Marseille, France

[13] Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium

[14] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy

[15] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Hematol Unit, Meldola, FC, Italy

[16] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[17] UZ Leuven, Dept Hematol, Leuven, Belgium

[18] Baylor Univ, Med Ctr, Dallas, TX USA

[19] Tata Med Ctr, Clin Hematol Oncol & HCT, Kolkata, India

[20] Punes Sahyadri Hosp, Pune, Maharashtra, India

[21] Sun Pharmaceut Ind Inc, Princeton, NJ USA

[22] Sun Pharma Adv Res Co Ltd, Mumbai, Maharashtra, India

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

309

引用

页数：6

共 50 条

[1] Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy
Cortes, Jorge E.
Kim, Dong-Wook
Nicolini, Franck E.
Saikia, Tapan
Charbonnier, Aude
Apperley, Jane F.
Rathnam, Krishna
Deininger, Michael W.
De Lavallade, Hugues
Khattry, Navin
Whiteley, Andrew
Mauro, Michael J.
Verhoef, Gregor
Gambacorti-Passerini, Carlo
Lucchesi, Alessandro
Apte, Shashikant
Nikki, Granacher
Yao, Siu-Long
Kothekar, Mudgal
Sreenivasan, Jayasree
Bimba, H., V
Chimote, Geetanjali
BLOOD, 2019, 134
[2] Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib
Cortes, Jorge E.
Saikia, Tapan
Kim, Dong-Wook
Alvarado, Yesid
Nicolini, Franck E.
Khattry, Navin
Rathnam, Krishnakumar
Apperley, Jane
Deininger, Michael W.
de Lavallade, Hugues
Charbonnier, Aude
Granacher, Nikki
Gambacorti-Passerini, Carlo
Lucchesi, Alessandro
Mauro, Michael J.
Verhoef, Gregor
Vandenberghe, Peter
Whiteley, Andrew R.
Apte, Shashikant
Yao, Siu-Long
Kothekar, Mudgal
Sreenivasan, Jayasree
Bimba, H., V
Chimote, Geetanjali
BLOOD, 2020, 136
[3] Impact of Polymorphisms in Pharmacokinetic Genes on Tyrosine Kinase Inhibitor (TKI) Tolerability in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
Patel, Jai N.
Lopes, Karine Eboli
Druhan, Lawrence J.
Zeng, Hang
Beam, Travis
Moore, Donald C.
Salem, Ahmed
Hamadeh, Issam
Savage, Quanisha
Chojecki, Aleksander L.
Ai, Jing
Knight, Thomas G.
Ragon, Brittany Knick
Shah, Nilay A.
Sanikommu, Srinivasa Reddy
Steuerwald, Nury M.
Smith, Mathew
Hamilton, Alicia
Rangavajhula, Keerthana
Bell, Ariel
Drummond, Kendra
Symanowski, James T.
Grunwald, Michael R.
BLOOD, 2022, 140 : 11530 - 11531
[4] Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph plus CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Cortes, Jorge E.
Saikia, Tapan
Kim, Dong-Wook
Alvarado, Yesid
Nicolini, Franck E.
Rathnam, Krishnakumar
Khattry, Navin
Punatar, Sachin
Apperley, Jane F.
Charbonnier, Aude
Deininger, Michael
de Lavallade, Hugues
Granacher, Nikki
Gambacorti-Passerini, Carlo
Lucchesi, Alessandro
Mauro, Michael
Vandenberghe, Peter
Verhoef, Gregor
Whiteley, Andrew R.
Nag, Arijit
Apte, Shashikant
Yao, Siu-Long
Inamdar, Sandeep
Dillu, Ruchika Irene
Sreenivasan, Jayasree
Chimote, Geetanjali
BLOOD, 2022, 140
[5] Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph plus ) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).
Maiti, Abhishek
Ravandi, Farhad
Cortes, Jorge E.
Jabbour, Elias
Marx, Kayleigh
Daver, Naval Guastad
Garcia-Manero, Guillermo
Konopleva, Marina
Benton, Christopher Brent
Masarova, Lucia
Dinardo, Courtney Denton
Bose, Prithviraj
Naqvi, Kiran
Pierce, Sherry A.
Kantarjian, Hagop M.
Short, Nicholas James
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
Qian, Jiang
Shi, Dayu
Li, Zongru
Qin, Yazhen
Zhao, Ting
Liu, Bingcheng
Chen, Zi
Niu, Qian
Men, Lichuang
Wang, Hengbang
Yang, Dajun
Zhai, Yifan
Huan, Xiaojun
BLOOD, 2021, 138
[7] An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Men, Lichuang
Wang, Hengbang
Ji, Jiao
Huang, Bo
Shi, Dayu
Zhao, Ting
Hou, Yue
Yang, Dajun
Zhai, Yifan
BLOOD, 2019, 134
[8] Optimal Interval for Detection of Molecular Relapse after Stop of Tyrosine Kinase Inhibitor (TKI) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Caliculated By Kinetics of BCR-ABL Transcripts
Miyamura, Koichi
Osaki, Masahide
Goto, Tatsunori
Morishita, Takanobu
Ozawa, Yukiyasu
BLOOD, 2020, 136
[9] Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph plus CML-CP)
Mukherjee, Sudipto
Cao, Xiting
Sadek, Islam
Maegawa, Rodrigo
Latremouille-Viau, Dominick
Pivneva, Irina
Guerin, Annie
Smith, B. Douglas
BLOOD, 2020, 136
[10] Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study
Jiang, Qian
Zhang, Yanli
Wang, Qiang
Weng, Jianyu
Liu, Zhenfang
Chen, Suning
Weiming, Li
Liu, Bingcheng
Liu, Zhuogang
Wang, Yihan
Cao, Jingrong
BLOOD, 2023, 142

← 1 2 3 4 5 →